VALEO PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.095 CAD | 0.00% |
|
-9.52% | -47.22% |
| 04-25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| 03-22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
| Sales 2024 * | 61M 44.6M 3.56B | Sales 2025 * | 75.83M 55.44M 4.43B | Capitalization | 9.37M 6.85M 547M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -13.16M -1.05B | Net income 2025 * | -12M -8.77M -701M | EV / Sales 2024 * | 1.01 x |
| Net Debt 2024 * | 52.53M 38.4M 3.07B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.12 x |
| P/E ratio 2024 * |
-0.48
x | P/E ratio 2025 * |
-0.73
x | Employees | 100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Valeo Pharma Inc.
More press releases
| 1 week | -9.52% | ||
| Current month | -13.64% | ||
| 1 month | -40.62% | ||
| 3 months | -45.71% | ||
| 6 months | -32.14% | ||
| Current year | -47.22% |
1 week
0.08
0.10
1 month
0.060.16
Current year
0.060.39
1 year
0.060.45
3 years
0.061.20
5 years
0.001.86
10 years
0.001.86
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 26/03/03 |
Pascal Tougas
DFI | Director of Finance/CFO | - | 11-19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 24/07/18 |
Steven Saviuk
FOU | Founder | 65 | 26/03/03 |
Marc Léger
BRD | Director/Board Member | 65 | 26/04/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 0.095 | 0.00% | 16 000 |
| 09/05/24 | 0.095 | -5.00% | 29,000 |
| 08/05/24 | 0.1 | +5.26% | 15,100 |
| 07/05/24 | 0.095 | 0.00% | 9,000 |
| 06/05/24 | 0.095 | -9.52% | 143,300 |
Delayed Quote Toronto S.E., May 10, 2024 at 04:49 pm
More quotes
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
03/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.095
CAD
Average target price
0.5
CAD
Spread / Average Target
+426.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.22% | 6.85M | |
| +30.68% | 695B | |
| +26.51% | 568B | |
| -4.45% | 361B | |
| +19.79% | 330B | |
| +3.75% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +8.18% | 168B |
- Stock Market
- Equities
- VPH Stock
